Market Update: Eli Lilly & Company (NYSE:LLY) – U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

[PR Newswire] – RIDGEFIELD, Conn., and INDIANAPOLIS, July 19, 2016 /PRNewswire/ — The U.S. Food and Drug Administration has approved an expanded indication for Synjardy® (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with type 2 diabetes (T2D). SYNJARDY, from Boehringer Ingelheim and Eli Lilly and Company (LLY), is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D when treatment with both empagliflozin and metformin is appropriate. SYNJARDY is a combination of empagliflozin (Jardiance®) and metformin — two medicines with complementary mechanisms of action — to help control blood glucose in adults with T2D. Read more on this. , with a current market cap of $recting to http://finance.ya, ended trading at $. Looking at today’s trading action, the company’s one day range from $ with its 52-week range being $. Priced at x this year’s forecasted earnings, LLY shares are relatively inexpensive compared to the industry’s x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $, which would be a $0.00 better than last year. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $0.00 . If realized, that would be a 0.00% decrease over the year-ago quarter. More recently, d LLY from to (/fi). Previously, d LLY from to . When considering if the stock is under or overvalued, the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Company Update (NYSE:LLY): FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote Stock Update (NYSE:LLY): Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation